Neurofibromatosis type 1 - selumetinib - initial authority application form (PB370)

Use this form to apply for initial PBS-subsidised treatment with selumetinib for patients aged between 2 to 18 years with neurofibromatosis type 1.

Page last updated: 6 August 2024.
QC 74418